Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients With or Without Hepatitis B or C Coinfection

REFERENCES

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10,2011; 1–166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. Accessed May 24,2011.
   Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hep-atotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Aquir Immune Defic Syndr. 200127: 426–431.
   Google Scholar
• Nunez M. Hepatotoxicity of antiretrovirals: inci-dence, mechanisms and management. J Hepatol. 2006;44:S132–S139.
   PubMed Web of Science ®Google Scholar
• Kandula V, Khanlou H, Farthing C. Tipranavir: a novel second-generation non-peptidic protease inhibitor. Expert Rev Anti Infect Ther. 2005;3:9–21.
   PubMedGoogle Scholar
• Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatoxicity associated with protease inhibi-tor-based antiretroviral regimens with or without concur-rent ritonavir. AIDS. 2004;18:2277–2284.
   PubMed Web of Science ®Google Scholar
• Perez-Elias MJ, Sanchez-Conde M, Soriano V, et al. Fosamprenavir (GW433908)/ ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Enferm lnfecc Microbiol Clin. 2009;27:28–32.
   PubMed Web of Science ®Google Scholar
• Pineda JA, Perez-Elias M-J, Pena JM, Luque I, Rodriguez-Alcantara F. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials. 2008;9:309–313.
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Lye P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir Into-navir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
   PubMed Web of Science ®Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482. Erratum in Lancet. 2006;368: 1238.
   PubMed Web of Science ®Google Scholar
• Cohen C, DeJesus E, LaMarca A, et al. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. HIV Clin Trials. 2010;11:239–247.
   PubMed Web of Science ®Google Scholar
• Young B, DeJesus E, LaMarca A, et al. Switching to fosamprenavir (FPV) led to similar efficacy and safety in HIV-1-infected subjects on their first PI regimen: a prospective, open-label, multicenter, randomized trial (ESS100290). Presented at: 17th International AIDS Conference, August 3–8, 2008, Mexico City, Mexico. Poster TUPE0067.
   Google Scholar
• Hicks CB, DeJesus E, Sloan LM, et al. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retrovi-ruses. 2009;25:395–403.
   PubMed Web of Science ®Google Scholar
• Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infec-tion: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
   PubMedGoogle Scholar
• Kumar P, De Jesus E, Huhn G, et al. SUPPORT (Study in Underrepresented Patient Populations of Regimen Toler-ability): 48-week results of fosamprenavir/ritonavir versus efavirenz with abacavir/lamivudine in antiretroviral-naive subjects. Presented at: Tenth International Congress on Drug Therapy in HIV Infection, November 7–11, 2010; Glasgow, Scotland. Poster P7.
   Google Scholar
• Wai C-T, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
   PubMed Web of Science ®Google Scholar
• Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut. 2006;55:409–414.
   PubMed Web of Science ®Google Scholar
• Mikl J, Sulkowski MS, Benhamou Y, et al. Hepatic profile analyses of tipranavir in phase ll and III clinical trials. BMC Infect Dis. 2009;9:203–213.
   PubMed Web of Science ®Google Scholar
• Fourie J, Flamm J, Rodriguez-French A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 201112: 313–322.
   Google Scholar
• Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials. 2007;8:213–220.
   PubMed Web of Science ®Google Scholar
• Reyataz (atazanavir sulfate). Prescribing information. Bristol-Myers Squibb; 2010.
   Google Scholar
• Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, ran-domized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603–2614.
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combina-tion with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011–1019.
   PubMed Web of Science ®Google Scholar
• Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1—infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323–332.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006,20:711–718.
   PubMed Web of Science ®Google Scholar